Low Estimates of HIV Seroconversions Among Clients of a Drug Treatment Clinic in San Francisco, 1995 to 1998
- 1 April 2000
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 23 (5) , 426-429
- https://doi.org/10.1097/00126334-200004150-00010
Abstract
Summary:Limited data exist on the distribution of HIV-1 subtypes in Côte d'Ivoire. The aim of this study is to describe the distribution of genetic subtypes of HIV-1 strains in six regions of Côte d'Ivoire. In 1997, we consecutively collected blood from 172 HIV-1-infected patients from six regional tuberculosis treatment centers. Peripheral blood mononuclear cells (PBMCs) from these people were analyzed by a restriction fragment-length polymorphism (RFLP) assay that involves a sequential endonuclease digestion of a 297-base pair polymerase chain reaction (PCR) fragment; plasma samples were tested by a V3-loop peptide enzyme immunoassay (PEIA). DNA sequencing of the protease or env genes was performed on all samples discordant in the two assays as well as a random sample of the concordant subtyped samples. Of 172 specimens, 3 were PCR-negative, and 169 were putatively classified as subtype A by RFLP. The 3 PCR-negative samples were unequivocally subtyped A by PEIA. Of the 169 RFLP subtype A samples, 159 (94%) were subtyped A by PEIA. Of the 10 discordant samples, PEIA testing classified 3 as subtype C, 2 as D, and 5 as F. Sequencing of the env gene classified these samples as 1 subtype A, 4 Ds, and 5 Gs. Thus, 163 (95%) of the specimens were subtype A, 3 subtype D, 4 subtype G, 1 A/D, and 1 A/G (IbNG) circulating recombinant forms (CRF). In conclusion, most HIV-1- infected tuberculosis patients throughout the interior of Côte d'Ivoire are infected with HIV-1subtype A, which are very likely the A/G (IbNG) CRF. The uniform distribution of this subtype makes Côte d'Ivoire a potential site for vaccine trials. Address correspondence and reprint requests to John N. Nkengasong. Laboratory of Virology, Projet RETRO-CI, 01 BP 1712 Abidjan, Côte d'Ivoire; email:[email protected] Use of trade names is for identification only and does not imply endorsement by the U.S. Centers for Disease Control and Prevention nor the U.S. Department of Health and Human Services. Manuscript received June 9, 1999; accepted November 24, 1999. © 2000 Lippincott Williams & Wilkins, Inc.Keywords
This publication has 11 references indexed in Scilit:
- Declining seroprevalence in a very large HIV epidemic: injecting drug users in New York City, 1991 to 1996.American Journal of Public Health, 1998
- Seroconversion Issues Among Out-of-Treatment Injection Drug UsersJournal of Psychoactive Drugs, 1998
- New Testing Strategy to Detect Early HIV-1 Infection for Use in Incidence Estimates and for Clinical and Prevention PurposesJAMA, 1998
- Retention, HIV risk, and illicit drug use during treatment: methadone dose and visit frequency.American Journal of Public Health, 1998
- Young and recent‐onset injecting drug users are at higher risk for HIVAddiction, 1997
- Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses.American Journal of Public Health, 1996
- The estimated prevalence and incidence of HIV in 96 large US metropolitan areas.American Journal of Public Health, 1996
- Trends in Human Immunodeficiency Virus Seroprevalence among Injection Drug Users Entering Drug Treatment Centers, United States, 1988-1993American Journal of Epidemiology, 1996
- Problems in interpreting HIV sentinel seroprevalence studiesAnnals of Epidemiology, 1995
- Methadone Maintenance and Needle/Syringe SharingInternational Journal of the Addictions, 1993